XML 14 R5.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc stockholders
Ordinary Shares
Deferred Shares
Additional Paid-in-Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2024     40,234,663 63,443        
Beginning balance at Dec. 31, 2024 $ 130,135 $ 130,029 $ 1 $ 86 $ 393,474 $ (237,664) $ (25,868) $ 106
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 468 468     468      
Issue of ordinary shares, net of issuance costs (in shares)     104,732          
Issue of ordinary shares, net of issuance costs 2 2 $ 0 [1]   2      
Foreign currency translation adjustments 4,646 4,643         4,643 3
Net loss (19,658) (19,648)       (19,648)   (10)
Ending balance (in shares) at Mar. 31, 2025     40,339,395 63,443        
Ending balance at Mar. 31, 2025 115,593 115,494 $ 1 $ 86 393,944 (257,312) (21,225) 99
Beginning balance (in shares) at Dec. 31, 2024     40,234,663 63,443        
Beginning balance at Dec. 31, 2024 130,135 130,029 $ 1 $ 86 393,474 (237,664) (25,868) 106
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Foreign currency translation adjustments 12,941              
Net loss (40,784)              
Ending balance (in shares) at Jun. 30, 2025     40,348,665 63,443        
Ending balance at Jun. 30, 2025 102,481 102,377 $ 1 $ 86 393,663 (278,436) (12,937) 104
Beginning balance (in shares) at Mar. 31, 2025     40,339,395 63,443        
Beginning balance at Mar. 31, 2025 115,593 115,494 $ 1 $ 86 393,944 (257,312) (21,225) 99
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation (281) (281)     (281)      
Issue of ordinary shares, net of issuance costs (in shares)     9,270          
Issue of ordinary shares, net of issuance costs [1] 0 0 $ 0   0      
Foreign currency translation adjustments 8,295 8,288         8,288 7
Net loss (21,126) (21,124)       (21,124)   (2)
Ending balance (in shares) at Jun. 30, 2025     40,348,665 63,443        
Ending balance at Jun. 30, 2025 102,481 102,377 $ 1 $ 86 393,663 (278,436) (12,937) 104
Beginning balance (in shares) at Dec. 31, 2025     40,848,893 63,443        
Beginning balance at Dec. 31, 2025 74,292 74,208 $ 1 $ 86 393,944 (304,092) (15,731) 84
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 556 556     556      
Foreign currency translation adjustments (2,836) (2,834)     (1) (5) (2,828) (2)
Net loss (5,534) (5,531)       (5,531)   (3)
Ending balance (in shares) at Mar. 31, 2026     40,848,893 63,443        
Ending balance at Mar. 31, 2026 66,478 66,399 $ 1 $ 86 394,499 (309,628) (18,559) 79
Beginning balance (in shares) at Dec. 31, 2025     40,848,893 63,443        
Beginning balance at Dec. 31, 2025 74,292 74,208 $ 1 $ 86 393,944 (304,092) (15,731) 84
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Foreign currency translation adjustments (2,014)              
Net loss (16,133)              
Ending balance (in shares) at Jun. 30, 2026     40,848,893 63,443        
Ending balance at Jun. 30, 2026 57,134 57,073 $ 1 $ 86 394,932 (320,208) (17,738) 61
Beginning balance (in shares) at Mar. 31, 2026     40,848,893 63,443        
Beginning balance at Mar. 31, 2026 66,478 66,399 $ 1 $ 86 394,499 (309,628) (18,559) 79
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Share based compensation 433 433     433      
Foreign currency translation adjustments 822 821         821 1
Net loss (10,599) (10,580)       (10,580)   (19)
Ending balance (in shares) at Jun. 30, 2026     40,848,893 63,443        
Ending balance at Jun. 30, 2026 $ 57,134 $ 57,073 $ 1 $ 86 $ 394,932 $ (320,208) $ (17,738) $ 61
[1] Indicates amount less than one thousand